A.J. Drexel Autism Institute, Drexel University, Philadelphia, Pa.
A.J. Drexel Autism Institute, Drexel University, Philadelphia, Pa.
Acad Pediatr. 2021 Mar;21(2):272-279. doi: 10.1016/j.acap.2020.05.015. Epub 2020 May 31.
Children with autism spectrum disorder (ASD) may benefit from medication to treat a diverse array of behaviors and health conditions common in this population including co-occurring conditions associated with ASD, such as attention-deficit/hyperactivity disorder (ADHD) and anxiety. However, prescribing guidelines are lacking and research providing national estimates of medication use in youth with ASD is scant. We examined a nationally representative sample of children and youth ages 6 to 17 with a current diagnosis of ASD to estimate the prevalence and correlates of psychotropic medication.
This study used data from the 2016 and 2017 National Survey of Children's Health. We estimated unadjusted prevalence rates and used multivariable logistic regression to estimate the odds of medication use in children and youth across 3 groups: those with ASD-only, those with ASD and ADHD, and those with ADHD-only.
Two thirds of children ages 6 to 11 and three quarters of youth ages 12 to 17 with ASD and ADHD were taking medication, similar to children (73%) and youth with ADHD-only (70%) and more than children (13%) and youth with ASD-only (22%). There were no correlates of medication use that were consistent across group and medication type. Youth with ASD and ADHD were more likely to be taking medication for emotion, concentration, or behavior than youth with ADHD-only, and nearly half took ASD-specific medication.
This study adds to the literature on medication use in children and youth with ASD, presenting recent, nationally representative estimates of high prevalence of psychotropic drug use among children with ASD and ADHD.
自闭症谱系障碍(ASD)患儿可能受益于药物治疗,以治疗该人群中常见的各种行为和健康状况,包括与 ASD 相关的共病,如注意力缺陷/多动障碍(ADHD)和焦虑症。然而,目前缺乏用药指导原则,且研究也很少提供全国 ASD 患儿用药情况的估计数据。我们调查了一个全国代表性的 6 至 17 岁 ASD 确诊患儿样本,以评估精神药物的使用情况及其相关因素。
本研究使用了 2016 年和 2017 年全国儿童健康调查的数据。我们估计了未经调整的流行率,并使用多变量逻辑回归估计了 ASD 单纯型、ASD 合并 ADHD 型和 ADHD 单纯型儿童和青少年使用药物的几率。
三分之二的 6 至 11 岁 ASD 合并 ADHD 患儿和四分之三的 12 至 17 岁 ASD 合并 ADHD 青少年正在服用药物,与 ADHD 单纯型患儿(73%)和青少年(70%)相似,且高于 ASD 单纯型患儿(13%)和青少年(22%)。在药物使用方面,没有与组群和药物类型相关的一致因素。与 ADHD 单纯型青少年相比,ASD 合并 ADHD 青少年更有可能服用药物治疗情绪、注意力或行为问题,近一半的人服用 ASD 特异性药物。
本研究增加了 ASD 患儿用药的文献,提供了 ASD 合并 ADHD 儿童和青少年精神药物使用高流行率的最新全国代表性估计数据。